Pure Biologics Spólka Akcyjna (PUR) — Cash Flow-to-Debt Ratio
Pure Biologics Spólka Akcyjna (PUR) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of zł-216.00K could theoretically repay 0% of its total liabilities (zł20.72 Million) in one year. See free cash flow generation of Pure Biologics Spólka Akcyjna to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pure Biologics Spólka Akcyjna Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Pure Biologics Spólka Akcyjna across 9 annual periods. Also explore Pure Biologics Spólka Akcyjna net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Pure Biologics Spólka Akcyjna (2016–2024)
Year-by-year debt coverage analysis for Pure Biologics Spólka Akcyjna. For market capitalisation and broader financial context, see PUR market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (PLN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.70x | zł-10.83 Million | zł15.46 Million | ▲ +37.2% |
| 2023 | -1.12x | zł-23.26 Million | zł20.84 Million | ▲ +5.6% |
| 2022 | -1.18x | zł-17.39 Million | zł14.71 Million | ▲ +62.1% |
| 2021 | -3.12x | zł-24.04 Million | zł7.70 Million | ▼ -4933.4% |
| 2020 | -0.06x | zł-1.35 Million | zł21.83 Million | ▼ -116.9% |
| 2019 | 0.37x | zł5.33 Million | zł14.57 Million | ▲ +164.1% |
| 2018 | -0.57x | zł-2.49 Million | zł4.36 Million | ▲ +77.6% |
| 2017 | -2.55x | zł-2.85 Million | zł1.12 Million | ▼ -130.0% |
| 2016 | -1.11x | zł-710.24K | zł640.12K | — |